Insider Signal Report — 2026-05-08
Scan covers trade_date 2026-05-03 → 2026-05-08 | 21 qualifying trades scanned | 2 signals detected
★★★★ Informed Accumulation
Criteria: Repeat Buyer + Prior 30d −10% to −20%
Insider with a prior purchase in the same ticker within 2 years, adding to position after a 10–20% pullback. Deep institutional knowledge + deliberate price discipline. EV ~20–30%+ at 12–15m. Cross-check business quality — serial buyers into structural decline are noise.
Target Hold: 12–15 months
| Ticker | Company | Trade Date | Insider | Title | Value | Prior 30d | C-Suite | New Pos | Also Qualifies |
|---|---|---|---|---|---|---|---|---|---|
| WTW | WILLIS TOWERS WATSON PLC | 2026-05-06 | Clarke Lucy | President of Risk & Broking | $499K | -13.3% | ✓ | — | — |
★★★★ Fresh Conviction Entry
Criteria: New Position + C-Suite + Drawdown ≥10%
C-suite executive initiating a brand-new position (no prior purchase in 2 years) after a ≥10% decline. Deliberate timing: they chose this specific entry point from scratch. ~50–55% win rate at 3–6m; works faster than repeat buyers. Target 6–9m hold.
Target Hold: 6–9 months
| Ticker | Company | Trade Date | Insider | Title | Value | Prior 30d | C-Suite | New Pos | Also Qualifies |
|---|---|---|---|---|---|---|---|---|---|
| WTW | WILLIS TOWERS WATSON PLC | 2026-05-04 | Hess Carl Aaron | Chief Executive Officer | $510K | -10.7% | ✓ | ✓ | — |
Notable Buys — No Strategy Match
Trades ≥$500,000 that didn't meet any strategy filter. Often in the −5% to 0% prior-return zone (weakest bucket) or missing price data.
| Ticker | Company | Trade Date | Insider | Title | Value | Prior 30d | C-Suite | New Pos | Also Qualifies |
|---|---|---|---|---|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, Inc. | 2026-05-04 | Kolchinsky Peter | maybe director | $52.2M | N/A | — | ✓ | — |
| COAG | Hemab Therapeutics Holdings, Inc. | 2026-05-04 | RA Capital Healthcare Fund LP | maybe director | $52.2M | N/A | — | ✓ | — |
| COAG | Hemab Therapeutics Holdings, Inc. | 2026-05-04 | RA Capital Nexus Fund II, L.P. | maybe director | $52.2M | N/A | — | ✓ | — |
| COAG | Hemab Therapeutics Holdings, Inc. | 2026-05-04 | RA Capital Nexus Fund IV, L.P. | maybe director | $52.2M | N/A | — | ✓ | — |
| COAG | Hemab Therapeutics Holdings, Inc. | 2026-05-04 | Shah Rajeev M. | maybe director | $52.2M | N/A | — | ✓ | — |
| ODTX | Odyssey Therapeutics, Inc. | 2026-05-08 | Dimension Capital II, L.P. | maybe director | $20.0M | N/A | — | ✓ | — |
| GEHC | GE HealthCare Technologies Inc. | 2026-05-06 | CULP H LAWRENCE JR | maybe director | $5.0M | -12.3% | — | ✓ | — |
| UPST | Upstart Holdings, Inc. | 2026-05-07 | Girouard Dave | maybe director | $5.0M | +9.6% | — | ✓ | — |
| POOL | POOL CORP | 2026-05-07 | PEREZ DE LA MESA MANUEL J | maybe director | $1.9M | -5.5% | — | — | — |
| ARE | ALEXANDRIA REAL ESTATE EQUITIES, IN | 2026-05-04 | MARCUS JOEL S | Executive Chairman | $1.1M | -4.4% | ✓ | — | — |
| ADP | AUTOMATIC DATA PROCESSING INC | 2026-05-07 | SWAN ROBERT HOLMES | maybe director | $746K | +5.1% | — | ✓ | — |
| L | LOEWS CORP | 2026-05-05 | Robusto Dino | maybe director | $527K | -1.5% | — | ✓ | — |
| NCLH | Norwegian Cruise Line Holdings Ltd. | 2026-05-07 | Byng-Thorne Zillah | maybe director | $521K | -8.1% | — | — | — |
Signal Summary
| Rating | Strategy | Signals |
|---|---|---|
| ★★★★★ | Conviction Bottom | 0 |
| ★★★★ | Informed Accumulation | 1 |
| ★★★★ | Fresh Conviction Entry | 1 |
| ★★★ | Momentum Confirmation | 0 |
| ★★ | Fallen Knife w/ Insider Backstop | 0 |
Generated 2026-05-08 · Strategies based on backtests 2021–2026 on US insider purchases